OHSU

Graduate Studies Faculty

« Back to Search List



Tomasz M. Beer, M.D., F.A.C.P.

Grover C. Bagby Endowed Chair for Prostate Cancer Research
Professor of Medicine, Hematology & Medical Oncology
Director, Prostate Cancer Research Program
Admin Unit: SOM-DOM Hematology & Medical Oncology
Phone: 503-494-4393
Fax: 503-494-6197
Office: Center for Health & Healing
Mail Code: CH14R
Programs:
Graduate Program in Clinical Nutrition
Research Interests:
prostate cancer, novel therapies, clinical trials and preclinical investigation
Preceptor Rotations
Academic Term Available Fall 2012 Yes Fall 2013 Yes Summer 2013 Yes
Faculty Mentorship
Dr. Beer is available as a mentor for 2012-2013. Dr. Beer is available as a mentor for 2013-2014. Dr. Beer is available as a mentor for 2014-2015.
Profile

Tomasz M. Beer, M.D., Grover C. Bagby Endowed Chair for Prostate Cancer Research,Professor of Medicine, Division of Hematology & Medical Oncology, and Deputy Director at the Oregon Health & Science University Knight Cancer Institute in Portland, Oregon.  Dr. Beer leads the Prostate Cancer Research Program within the OHSU Knight Cancer Institute, an NCI-designated Cancer Center.  He received his medical degree from Johns Hopkins School of Medicine, Baltimore, Maryland, in 1991.  He then moved to Oregon Health & Science University.  At OHSU he completed his internship and residency in internal medicine and then completed his fellowship in Hematology and Medical Oncology.  Currently, he is a fellow of the American College of Physicians, as well as a member of several other professional societies, including American Society of Clinical Oncology, American Urologic Association, American Association for Cancer Research, and Southwest Oncology Group, where he has led a number of clinical trials.  Dr. Beer has authored and co-authored more than 250 articles and abstracts on prostate cancer largely with a focus on the development of novel therapies through clinical and translational investigation.  Dr. Beer’s major research interests include clinical trials, preclinical investigation, and risk factors in prostate cancer.